ChartMill · Sep 9, 2026
Stay updated with the stocks that are on the move in today's after-hours session.
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
GN
NASDAQ · GNLX
Genelux Corporation
Healthcare · Biotechnology
$2.34
Down-$0.13 (-5.26%)
Updated Sep 17, 2026, 12:14 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 167.81M
- P/E ratio
- -5.24
- Dividend yield
- 0.00%
- 52-week range
- $2.29 – $3.25
- Volume
- 661.72K
- Avg. volume
- 233.63K
Price performance
GNLX price history
1M range · 0 trading sessions · Daily adjusted prices
GNLX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest GNLX news
The latest Smart Investors Daily articles mentioning GNLX.
Stock researchCompany · Overview
GNLX research
Overview
Company profile and research snapshot.
Company profile
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $17.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 20, 2026 | Benchmark | Speculative Buy | — |
| Oct 21, 2025 | Lake Street | Buy | — |
| Jul 21, 2025 | LUCID CAPITAL MARKETS | Buy | — |
| May 8, 2025 | Benchmark | Speculative Buy | — |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 9, 2026
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient also achieved 84.6% reduction in target lesion size, as previously reported by Genelux, exceeding the reduction achieved following first-line therapy -- -- Findings support the potential of systemically administered Olvi-Vec to drive anti-tumor activity and enhance responsiveness t
Benzinga · Sep 9, 2026
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON) shares rose
Benzinga · Sep 4, 2026
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market session. The market value of their outstanding shares is at $3.8 million. Genelux (NASDAQ:GNLX) stock moved upwards by
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
